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The gene spa P (formerly designated as spa Pl) encoding the M, 185,000 surface antigen (I/II) of Streptococcus mutans, serotype c (NGS), has 
been sequenced. The gene (4683 bp) encodes a protein of 1561 amino acid residues including putative signal peptide (residues I-38) and transmem- 
brane (residues 1537-1556) sequences. The N-terminal region (6(r550) has alanine-rich repeats and is predicted to be a-helical. However, the C-ter- 
minal region (800-1540) is proline-rich and favours an extended structure. Except for a short central variable region the sequences appear to be 
highly conserved for S. mutuns erotype c. N-Terminal sequencing of separated antigen I and antigen II polypeptides uggests that the former 
represents the N-terminal and the latter the C-terminal portions of the intact antigen. 
Antigen I/II; Streptococcal surface antigen; spa PI 
1. INTRODUCTION 
Streptococcus mutans is a microorganism commonly 
found in the human oral cavity and is responsible for 
dental caries [ 11. Investigations of the protein composi- 
tion of S. mutans revealed 4 antigens: I, II, III and I/II 
[2]. Of these, antigen I/II [3] is of particular 
significance, as it is a cell surface [4,5], immuno- 
dominant antigen which elicits serum IgG antibodies [6] 
and T cell helper or suppressor functions [7]. The anti- 
gen is a glycoprotein of approximate M, = 185,000, also 
termed antigen B [B] and Pl [9] and may function as a 
virulence factor [lo]. Immunisation studies with the 
whole organism [ 11,121, as well as the M, 185,000 an- 
tigen I/II prevented colonisation of S. mutans and the 
development of dental caries in non-human primates 
[6,13 .] It was suggested that antigen I/II may function 
as an adhesin by virtue of its hydrophobicity [14]. In- 
deed, construction of antigen I/II deficient mutants by 
insertional inactivation to the spa P gene has establish- 
ed that the cell surface hydrophobicity of the mutant 
organism is decreased [15] and that this surface protein 
functions as an adhesin for binding to salivary ag- 
glutinin coated hydroxyapatite beads [ 161. Further- 
more, monoclonal antibodies raised against the strep- 
tococcal antigen I/II [17] were applied in local passive 
immunisation experiments in non-human primates and 
prevented colonisation of S. mutans and the develop- 
ment of dental caries [18]. This is consistent with the 
concept that antigen I/II functions as an adhesin. An 
extensive series of in vivo studies in human subjects has 
established that some monoclonal antibodies to antigen 
I/II can prevent colonisation of S. mutans and that this 
is a function of the F(ab)z fragment of the antibody 
[19,20]. 
Antigen I and antigen II, although both present in the 
intact surface antigen of M, = 185,000, are serologically 
distinguishable and have been separated biochemically 
[3,21]. Antigen I was identified as a polypeptide of ap- 
proximate M, = 150,000 which was purified from 
culture supernatants of S. mutans. In contrast, antigen 
II was only separated following proteolysis of antigen 
I/II (a process which destroyed antigen I) as a polypep- 
tide of approximate M, = 50,000. Recently, cloning of 
the gene, termed spa P, encoding antigen I/II (Pl) of S. 
mutans strain NG5 (serotype c) was reported [22]. The 
cloned spa P was present in a 5.2 kb fragment derived 
by partial digestion of genomic DNA with Hind III. 
Cloning of the identical gene from another S. mutans 
strain (MT8148) was also reported [23]. 
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In this report the complete nucleotide sequence of spa 
P is presented, together with the predicted amino acid 
sequence. N-Terminal amino acid sequencing of the 
purified antigens I and II suggests that antigen I is pre- 
sent in the N-terminal and antigen II in the C-terminal 
portions of the 1?4, 185,000 antigen. 
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2. MATERIALS AND METHODS 
2.1. Nucleotide sequencing 
Restriction fragments from the recombinant clone pSM2949 [22] 
were subcloned into Ml3 mp18 or Ml3 mp19. The sequence of spa P 
was determined on both strands using the dideoxy chain termination 
procedure [24]. Double stranded PCR products (see below) were se- 
quenced directly using a modified procedure [25]. Synthetic primers 
(17-20 nucleotides) were used to sequence fragments > 400 bases. Se- 
quences were assembled and analysed using the Staden plus pro- 
gramme (Amersham, England). 
2.2, Polymerase chain reaction (PCR) 
Chromosomal DNA was urenared from S. mutans NGS as describ- 
(nucleotides 3985-4002 from the NGS sequence) and AAGGCAGT- 
GCGAAGTACC (complementary tonucleotides 5153-5170 from the 
MT8148 sequence [23]) a 1 kb fragment which included the 3’region 
of spa P was amplified by the PCR 1261 (30 cycles: 94’C for 2 min. 
55°C for 1 min. 72°C for 2 min). 
2.3. Protein purification and sequence analysis 
Antigen I/II and the separated antigens I and II were purified from 
S. mutans serotype c (Guy’s strain) as described [3,21]. A peptide of 
M,= 4000 was isolated from a subtilisin digest of antigen I/II [27]. A 
recombinant antigen of M,= 155,008 was prepared by gel filtration of 
the periplasmic fraction, released following osmotic shock from E. 
coli LC 137 transformed with pSM2949 [22]. Purified proteins 
(100-200 pmol) were subjected to Edman degradation, using the 470A 
eas nhase seouencer with on line 120A PTH analyser (Applied 
iiios;stems). - ed previously [22]. Using the primers CAAATGGGACAAACAGGC 
Fig. 1. Sequence of spa P from S. mutans. The most probable - 35 and - 10 promoter regions and Shine-Dalgarno sequence (SD) are underlined 
as is the 3 Hind III site (H) of pSM2949. Amino acid residues underlined are those determined by direct protein sequencing. Repeating amino acid 
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3. RESULTS 
The complete nucleotide sequence of the gene (4683 
bp) encoding antigen I/II and the deduced amino acid 
sequence is shown in fig. 1. An open reading frame from 
position 100-4782, as shown, was identified coding for 
a polypeptide of 1561 residues. The most probable - 10 
and - 35 promoter sequences are underlined as is a 
putative Shine-Dalgarno sequence. The full sequence of 
the pSM2949 insert includes approximately 800 bases 5 ’ 
to that shown in fig. 1. In order to confirm the reading 
frame, N-terminal amino acid sequence analyses were 
performed on intact native antigen I/II, recombinant 
gene products, as well as a number of fragments derived 
from antigen I/II with the results shown in fig.2. In 
each case the amino acid sequence determined matched 
that predicted from the nucleotide sequence. The N- 
terminal sequence of the recombinant Mr 155,000 an- 
tigen I/II corresponded to the predicted sequence from 
Asp-39 to Gln-67. Similarly the N-terminal residues of 
a purified M, 185,000 antigen I/II and a M, 150,000 an- 
tigen I showed the same partial sequence, suggesting 
that the N-terminal 38 residues represent a signal pep- 
tide. The predicted polypeptide h4, of the mature pro- 
tein, after the signal peptide cleavage, is 166,159 which 
is lower than the value determined by SDS-PAGE. The 
sequences are bracketed. Amino acid substitutions relative to the sequence of S. mutans train MT8148 are marked(*). A potential signal peptide 
cleavage site is arrowed. The N-terminal residue of antigen I is Asp-39 and of antigen II is Pro-997 (also indicated in fig.2). 
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Fig.2 N-Terminal sequence of antigen I/II and derived peptides. Recombinant antigen I/II (ret 155,GtW) was purified from E. coli transformed 
with plasmid pSM2949. Residues are numbered as for the sequence of strain NG5. - indicates no residue identified. 
difference may be due to glycosylation or to the 
presence of the Pro-rich sequences which would result 
in anom~ous ele~trophoretic migration. 
Comparison with the sequence of Okahashi et al. [23] 
suggested that the complete reading frame comprised a 
further 800 bases beyond the 3 ’ Hind III site. By means 
of the PCR, and using primers based on the sequences 
of 5’. mutans strains NG5 and MT8148, a 1 kb DNA 
fragment which overlapped with the pSM2949 insert 
was generated from S. mutans NG5 DNA. Sequencing 
of the PCR product confirmed that it encoded the entire 
C-terminal region of antigen I/II, as evidenced by the 
presence of a termination codon at nucleotides 
4783-4785. 
The predicted amino acid sequence of antigen I/II in- 
cludes a potential transmembrane region located at the 
C-terminus of the protein (Ala-1537-Leu-1556). Im- 
mediately preceding this is a sequence rich in Pro and 
otherwise consisting almost entirely of polar residues 
(Thr-1486-Asn-1536). Similar sequences present in 
other streptococcal cell surface proteins are believed to 
758 
LaY T R A S E P G S G 
span the cell wall [28]. Residues 847-963 represent 3 
tandem repeats of a Pro-rich 39 residue sequence and 
residues 219-464 represent 3 tandem repeats of an Ala- 
rich sequence. Residues 136-218 may represent a fur- 
ther degenerate repeat of the latter sequence. These 
results are consistent with those for the S. mutans train 
MT8148 gene sequence [23]. 
The sequences from the two S. mutans trains (NG5 
and MT8148), are highly conserved, with most 
nucleotide substitutions reflecting the use of alternative 
codons or resulting in conservative amino acid substitu- 
tions. There are 36 single amino acid substitutions 
distributed throughout the protein. Two short stretches 
within the region encoding amino acid residues 
750-805, however, showed considerably more varia- 
tion. Sequence comparison between these strains and 
with the corresponding region of the analogous surface 
antigen from S. sobrinus (spa A, PAg) [29], as shown in 
fig.3, indicates that in the region 750-756 a single 
residue deletion has occurred in strain MT8148, as well 
as 4 substitutions. In the region 795-805 a sequence of 
ET- - - - - 
no 809 
Fig.3. Sequence comparison of variabie region of antigen I/II from 5’. mutans trains NC5 and MT8148 and antigen PAg (spa A) from S. sobr&nis 
strain MT3791 [28]. Identical amino acid residues are boxed. 
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9 amino acid residues in strain NG5 is replaced with a 
non-homologous sequence of 14 residues in strain 
MT8148. 
From the N-terminal sequences, the positions of an- 
tigen I and antigen II were identified. Thus, antigen I 
extends from the N-terminus of the M, 185,000 surface 
antigen. Depending on the contribution of any post- 
translational modifications to the M, it may extend to 
residues 1390-1400 (see below), and would therefore 
show some overlap with the antigen II region. Antigen 
II extends from residue 997 and thus forms most or all 
of the C-terminal region. 
4. DISCUSSION 
The predicted sequence of antigen I/II is consistent 
with that of a cell surface protein, anchored in the mem- 
brane by the C-terminal region. The particularly high 
level of release of antigen I/II into culture super- 
natants, observed for the NG5 strain [30], is not 
therefore due to the presence of a truncated gene. 
Release of antigen I into culture supernatants of S. 
mutans is presumably the result of a cleavage at the C- 
terminal region by endogenous proteases. Similarly 
release of an N-terminal fragment was reported for the 
wall-associated antigen III (protein A) [31], although in 
neither case is the functional significance, if any, clear. 
The finding that the subtilisin cleaved Mr 4000 peptide 
reacts with rabbit antisera against antigen I [27] sug- 
gests that this peptide is derived from the C-terminal 
region of antigen I. Thus, antigen I may well extend as 
far as residues 1390-1400 and potential cleavage sites 
would be the clusters of Lys located between residues 
1396 and 1440. 
The N-terminal region of the protein which includes 
the Ala-rich repeats between residues 60 and 550 is 
predicted to be a-helical [32]. The relative abundance of 
Pro in the C-terminal region, i.e. residues 800-1540, 
would preclude the formation of a tightly folded struc- 
ture but would favour a rather extended structure. The 
sequence which shows variation between the two strains 
(750-805) falls between these two regions and may 
represent a conformationally less constrained part of 
the molecule. Takahashi et al. [29] have shown signifi- 
cant homology between PAg from S. sobrinus and the 
analogous antigen (PAc, I/II) in S. mutans to be 
restricted to residues 612-919 of the S. mutans 
molecule. This region should include cross-reactive 
epitopes accounting for the reported immunological 
relationships between these organisms. 
In view of the interest in antigen I/II as a component 
of an anti-caries vaccine, the demonstration that there 
is limited strain variation is of some importance. In this 
respect antigen I/II shows similar properties to the wall- 
associated protein antigen III (A) [3 11. Cross-reactivity 
between S. mutans and heart tissue has been raised as a 
serious objection to vaccination [33]. Later publications 
claimed that the heart cross-reactive antigen resides in 
the M, 185,000 streptococcal antigen I/II [9,13,34]. 
However, immunisation with antigen I/II of non- 
human primates failed to elicit heart cross-reactive an- 
tibodies [35]. Indeed, little homology was found be- 
tween the sequence of antigen I/II and that of M pro- 
tein in S. pyogenes causing rheumatic carditis [23]. Fur- 
thermore, a mutant of S. mutans, devoid of expressing 
antigen I/II yielded on immunisation heart cross- 
reactive antibody titres similar to those elicited by the 
antigen I/II intact strain [36]. These findings suggest 
that antigen I/II does not have heart cross-reactive pro- 
perties which instead may reside in the ccl membrane 
[37]. Indeed, a M, 62,000 membrane antigen was iden- 
tified, having myosin-like epitopes. 
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